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Abstract
FUNCTIONAL AND BIOCHEMICAL CONSEQUENCES OF SINGLE
NUCLEOTIDE POLYMORPHISMS IN THE HUMAN VESICULAR
MONOAMINE TRANSPORTER 1 GENE (SLC18A1)

By Sally Gamal Shukry, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Biology at Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Major Advisor: Jennifer K. Stewart
Associate Professor and Graduate Director, Department of Biology
Single nucleotide polymorphisms (SNP) in the human VMAT1 gene (SLC18A1) have
been associated with schizophrenia in three different populations: Han Chinese, Western European
and Japanese. Effects of these mutations on transport function of the hVMAT1 protein have not
been reported. The goal of this study was to investigate functional and biochemical differences in
human VMAT1 proteins with a threonine or proline at amino acid position 4 (Thr4Pro) and a
serine or threonine at position 98 (Ser98Thr). COS1 cells were transfected with variant SNPs

coding for 4Thr/98Ser, 4Pro/98Ser, or 4Thr98Thr. Western blotting demonstrated robust over
expression of the genes and no differences in electrophoretic mobility of the proteins. Maximal
transport of serotonin by the VMAT1 protein with 4Pro/98Ser was less than that of the 4Thr/98Ser
or the 4Thr/98Thr. Response of the 4Pro/Ser98 to the VMAT inhibitor reserpine was lower than
that of the 4Thr/98Thr. These findings suggest mechanisms for human VMAT1 links to
schizophrenia.

Introduction

A Brief Background on Vesicular Monoamine Transporters
Vesicular monoamine transporters (VMATs) are 55 kD transport proteins that are
embedded in the membranes of intracellular vesicles (5;27). VMAT proteins are members
of the Solute Carrier gene family (SLC18) that transport monoamines such as
norepinephrine, dopamine, and serotonin into storage vesicles to allow subsequent release
of the vesicle contents into a synapse or other extracellular space (10). Two major
VMATs, VMAT1 and VMAT2, are 60% identical in terms of their amino acid sequences.
VMAT1 (known as the chromaffin granule amine transporter) is found in extraneural
tissues including the chromaffin cells of the adrenal medulla and endocrine and paracrine
cells of the GI tract. VMAT2 (known as the synaptic vesicular monoamine transporter) is
primarily located in neuronal cells of the central, peripheral and enteric nervous systems
(8;19). By accumulating newly synthesized neurotransmitter molecules and freshly
returned neurotransmitters from the synapse, VMAT2 plays a critical role in the various
signaling processes between monoamine neurons (18). VMAT1 serves a similar role in
adrenal medulla and neuroendocrine cells.
Although VMAT2 is the major VMAT in human and rodent brain (8;19), Karen
Brennan-Ashe of the Stewart lab at Virginia Commonwealth University detected VMAT1
mRNA in the mouse medulla oblongata with the reverse transcriptase polymerase chain

reaction (RT-PCR) (1). The novel finding of VMAT1 in human post mortem brain by
Lohoff et al. with RT-PCR and Western Blots further increased interest in the localization
of VMAT1 in the human brain (13). The highest levels of human VMAT1 were identified
in the substantia nigra, amygdala and hippocampus (13).

A Look At How VMATs Work
Like plasma membrane transporters such as the dopamine transporter (DAT),
serotonin transporter (SERT), and norepinepherine transporter (NET), VMATs display a
similar size and topography with 12 transmembrane domains and both C-terminal and Nterminals tails in the vesicle’s interior (11;17), and Figure 2). Vesicular monoamine
transporters differ from other membrane transporters in several ways. Most importantly,
VMAT utilizes a proton gradient energetically to transport substrates rather than the
Na+/K+ gradient used by DAT, SERT, and NET (25). The proton gradient is established
across the vesicular membrane, which is created by a vacuolar ATPase (not directly
associated with the transporter) in its antiport activity, exchanging two protons for each
monoamine taken into the vesicle (22). Once the first proton is bound to the transporter, a
conformational change exposes a high affinity binding site. Binding of the second proton
causes the monoamine to be transported into the vesicular space (26). During an action
potential, vesicles move to the cell membrane and contents of the vesicle are discharged
into the extracellular space by exocytosis (10).
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The Link Between VMAT and Schizophrenia
Human VMAT1 is located on chromosome 8. There are 484 annotated genes
located on 8p 21-22; many of which are proto-oncogenes and tumor-suppressor genes (24).
This region of the genome also is one of the regions most implicated for susceptibility to
schizophrenia and bipolar disorders. Roughly 8.5% of the genes contained on 8p are
believed to contribute to neuropsychiatric disorders such as schizophrenia, autism, bipolar
disorders and depression (12). They are also implicated in neurodegenerative disorders
such as Parkinson’s and Alzheimer’s disease (24).
A number of single nucleotide polymorphisms (SNP) have been identified in the
human Vmat1 gene (SLC18A1), SNPs are DNA sequence variations that occur when a
single nucleotide (A, T, G or C) differs among members of a species, and geneticists are
particularly interested in whether SNPs in human genes are more common in individuals
with a specific disorder.
Based on the Vmat1 gene location on chromosome 8, Bly tested the hypothesis that
a VMAT1 SNP is associated with schizophrenia. Sequenced DNA from post-mortem
brain tissue of schizophrenic Caucasians revealed a statistically significant association with
a homozygous SNP in exon 3 of the SLC18A1 gene. This single base change, A277C
(numbering based on GenBank Accession # NM_003153.3), resulted in a single amino
acid change in the primary sequence of VMAT1 that produced a proline rather than a
threonine at amino acid 4. The CC genotype coding for the proline was observed in 21.4%
5

of the schizophrenic group compared to 2.6% in the control group (2). This finding was
supported by identification of the same SNP linked to schizophrenia in a Han Chinese
population (3). Additionally, two other laboratories have reported statistically significant
associations of this and other SNPs of the Vmat1 gene with either schizophrenia or bipolar
disorder in populations of European and Japanese descent (14;20). Three SNPs in the
coding region of the human Vmat1 gene that have been associated with schizophrenia are
listed in Table 1. A partial sequence of the VMAT1 cDNA NM_003053 illustrating the
position of SNPs in the coding region is shown in Figure 1. The predicted structure of the
human VMAT1 protein is shown in Figure 2.

Table 1. Single Nucleotide Polymorphisms In The Human VMAT1 gene SLC18A1
*SNP ID

+

NM_003053.3
SNP Alleles Major SNP
Major
Bases &
Allele
RNAAmino
NP_003044.1
Acid
Amino Acids
rs2270641
A277C Thr4 Pro
T/G
T
AThr
rs2270637
G560C Ser98Thr
C/G
C
GSer
rs1390938
T674C Thr136Ile
A/G
G
CThr
*SNP ID from the NCBI SNP data base and + GenBank Accession Numbers
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C
268 ATG CTC CGG ACC ATT CTG GAT GCT CCC CAG CGG TTG CTG AAG GAG GGG AGA GCG TCC CGG
M L
R P/T I
L
D
A
P
Q
R
L
L
K
E
G
R
A
S
R
328 CAG CTG GTG CTG GTG GTG GTA TTC GTC GCT TTG CTC CTG GAC AAC ATG CTG TTT ACT GTG
Q
L
V
L
V
V
V
F
V
A
L
L
L
D
N
M
L
F
T
V
388 GTG GTG CCA ATT GTG CCC ACC TTC CTA TAT GAC ATG GAG TTC AAA GAA GTC AAC TCT TCT
V
V
P
I
V
P
T
F
L
Y
D
M
E
F
K
E
V
N
S
S
448 CTG CAC CTC GGC CAT GCC GGA AGT TCC CCA CAT GCC CTC GCC TCT CCT GCC TTT TCC ACC
L
H
L
G
H
A
G
S
S
P
H
A
L
A
S
P
A
F
S
T
C
508 ATC TTC TCC TTC TTC AAC AAC AAC ACC GTG GCT GTT GAA GAA AGC GTA CCT AGT GGA ATA
I
F
S
F
F
N
N
N
T
V
A
V
E
E
S
V
P S/T G
I
568 GCA TGG ATG AAT GAC ACT GCC AGC ACC ATC CCA CCT CCA GCC ACT GAA GCC ATC TCA GCT
A
W
M
N
D
T
A
S
T
I
P
P
P
A
T
E
A
I
S
A
T
628 CAT AAA AAC AAC TGC TTG CAA GGC ACA GGT TTC TTG GAG GAA GAG ACT ACC CGG GTC GGG
H
K
N
N
C
L
Q
G
T
G
F
L
E
E
E T/I T
R
V
G
688 GTT CTG TTT GCT TCA AAG GCT GTG ATG CAA CTT CTG GTC AAC CCA TTC GTG GGC CCT CTC
V
L
F
A
S
K
A
V
M
Q
L
L
V
N
P
F
V
G
P
L

Figure. 1. Partial Sequence of NM_003053 (SLC18A1) with variants. Numbers are
initial base numbers of codons of VMAT1 mRNA (GenBank Accession # NM_003053.
Letters below the codons are standard amino acid abbreviations. Polymorphisms are
highlighted in yellow, and the alternate base is above the codon.
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SER98THR

Figure 2. Structure of the human VMAT1 protein
predicted with
ILE136THR
LUMEN

THR4PRO

CYTOPLASM

Figure 2. Predicted structure of the human VMAT1 protein. HMMTOP software
(http://www.enzim.hu/hmmtop/html/document.html) was used to generate the structure
from the translated protein sequence NP_003044.1 = protein coded by NM_003053
mRNA.
Evidence is compelling for association of these SNPs shown in Figure 1 with
psychiatric disorders, butt there is no information on functional consequences of any of
these SNPs. As shown in Figure 2, amino acid 4 is located in the N-terminal cytoplasmic
tail of the transport protein, and amino acids 98 and 136 are located in the first intravesicular loop. Both cytoplasmic and intravesicular regions are postulated to interact with
8

substrates and inhibitors (16;23), but specific effects of the amino acid changes on
VMAT1 transport activity are not known. The goal of this study was to address this
question by creating specific mutations in the human VMAT1 gene, transfecting the genes
into COS1 cells and evaluating effects on the transport activity of protein expressed in the
cells. The initial reference gene used in this study coded for the haplotype Thr4 Ser98
Ile136. This haplotype was chosen as the reference based on genetic evidence that the
alternate alleles are associated with schizophrenia or related disorders. The 4Pro and
Thr98 are linked to schizophrenia (2;3;14;20), and the 136 Ile is associated with partial
protection against bipolar disorder (13).
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Materials and Methods
Cells
The COS-1 kidney fibroblast cell line was obtained from American Type Culture
Collection (ATCC # 30-2002, Manassas, VA). Cells were maintained at 37° C with 5%
CO2 in DMEM medium (# 30-2002, ATCC) containing 4 mM L-glutamine, 4.5 g/L
glucose and 1.5g/L sodium bicarbonate. COS-1 medium is supplemented with 10% heat
inactivated fetal bovine serum, 100 units/ml penicillin and 100 units/ml streptomycin.

Site-directed mutagenesis
The VMAT1 clone with the reference sequence coding for 4Thr/98Ser/136 Ile was
obtained from Origene - SC122643 in the pCMV6-Neo vector. Primers designed by our
research team and used for mutagenesis by the VCU Molecular Laboratory are shown in
Table 2. Variant genes were inserted into expression vectors, amplified in E.coli (end Aand Rec A-) and the plasmids purified in megapreps by the VCU Molecular Biology Core.
Incubations were at 30 º C as recommended by Origene. Full length sequencing by
Operon (Huntsville, AL) verified all mutations and absence of recombination during
cloning.

10

Table 2. Mutagenesis Primers
Amino
Acid
Change to
4 Pro S
AS
98 Ser S
AS

Sense (S)/Antisense (AS)
ATCACCATGCTCCGGCCCATTCTGGATGCTC/
GAGCATCCAGAATGGGCCGGAGCATGGTGAT.
GTTGAAGAAAGCGTACCTACTGGAATAGCATGGATGAATG/
CATTCATCCATGCTATTCCAGTAGGTACGCTTTCTTCAAC.

Cell Transfection
To examine VMAT1 expression, COS-1 kidney fibroblasts were transfected with
the VMAT1 cDNA according to the protocol of Finn et al. (9). Cells were grown to
confluence in T-75 flasks (CoStar, Fisher Scientific) and fed 24 hours prior to
electroporation. In preparation for electroporation and transfection, cells were rinsed with
calcium-free/magnesium-free phosphate buffered saline (PBS) and detached with 0.25%
trypsin and 0.03% EDTA. Cells were returned to medium containing serum to inactivate
the trypsin and pelleted by centrifugation at 500 x g for 10 minutes at 4 °C. The cells were
resuspended in 800 µl of pre-warmed PBS containing calcium and magnesium
(Invitrogen). The cell suspension and 15 µg of DNA were transferred to a 0.4 cm gap
cuvette in the gene Pulser II (Biorad, Hercules, CA) and electroporated at 0.4 kV and 975
µF. Cells were plated in T-75 flasks and incubated for three-4 days prior to preparation of
membranes for transport assays or lysis for western analysis. The expression vector has a
neomyocin resistance gene, and cells incorporating the plasmid were selected by growth in
medium with geneticin (500 µg/ml).
11

Membrane Preparation
On the fourth day after electroporation, COS-1 cells from each T-75 flasks were
rinsed with PBS, detached and pelleted with centrifugation as described above. The pellet
was washed twice in PBS, centrifuged after each wash and resuspended in 200 µl of
sucrose-Hepes buffer (SH) containing 0.32 M sucrose in 10 mM Hepes adjusted to pH 7.4
with 1 M KOH and supplemented with proteolytic inhibitors (2 ug/ml aprotinin and
leupeptin 1 ug/ml pepstatin A and E-64, and 0.2 mM phenylmethylsulfonylfluoride
(PMSF). The suspension was transferred to a 1.5 ml tube and homogenized by sonication
at 4 pulses, 0.5 seconds per pulse, to yield approximately 3 Watts power. After the
suspension was centrifuged at 500 x g for 10 minutes at 4 °C, the supernatant was
immediately removed to a tube on ice. Total protein was measured with the Bio-Rad
protein assay (Bio-Rad Laboratories, Hercules, CA). Aliquots of the supernatant were
stored at – 70 °C until assayed for VMAT activity.
Western Blotting
Membrane proteins were separated by electrophoresis on 10% polyacrylamide gels
and transferred to nitrocellulose. Blots were incubated for an hour at 24 ˚C in blocking
solution containing Tris Buffered Saline (TBS) and 3% dry milk, and then incubated
overnight at 4 C with primary goat anti-human VMAT1 antibody C-19 (#SC-7718, Santa
Cruz Biotechnology, Santa Cruz, CA) diluted 1:200 in TBS + 0.1% Tween-20 (TBST).
Blots were washed with TBST and incubated for an hour at 24 °C with 1:10,000 donkey
12

anti-goat IgG-horseradish peroxidase (Santa Cruz). The blots were visualized with
enhanced chemiluminesence (Amersham, Biosciences, UK).

VMAT Uptake Assay
Each assay tube contained 50 µg of cell protein, 5 mM ATP, 0.25 mM ascorbic
acid, and 20 nM radiolabeled serotonin (3H-5HT) = 5-H[G-3H]T creatine sulfate 27 Ci /
mmol (American Radiolabeled Chemicals, Saint Louis, Mo), except in saturation
experiments in which increasing concentrations of labeled + unlabeled serotonin were
incubated to achieve saturation. Reactions were in a total volume of 200 µl of uptake
buffer. Incubations were conducted at 27°C for 5 minutes, except in time course
experiments or in saturation assays in which incubation was for 1.5 min to approximate
initial velocity of transport. The reaction was terminated by addition of 1 ml cold SH
buffer, rapidly filtered through 0.2 µm Supor 200 membranes (Pall/Gelman # 60300), and
washed with twice with 1 ml of cold SH buffer in a Millipore sampling manifold. Filters
were transferred to 10 ml of Scintisafe 50% Plus scintillation fluid (Fisher Scientific,) and
radioactivity was measured with a Beckman LS6000IC scintillation counter.

Statistics
Statistical analyses were as follows: For comparisons of VMAT1 activity at
various time points, a split-plot two-way analysis of variance (ANOVA with groups as
between-subjects factor and time as the within-subjects factor) and Newman Keuls’ post13

hoc tests were used. For comparison of activity measured at 5 min a one-way ANOVA
and Newman Keul’s post hoc was used. For transport kinetics and inhibition curves, best
fit non-linear regressions were performed on data from 3 different transfections of each
variant, and significant differences were determined from the 95% confidence limits of the
regressions. ANOVAs and non-linear regressions were performed with GraphPad Prism 5.
(GraphPad Software, Inc., La Jolla, CA).
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Results

Expression of hVMAT1 Variants in Transfected Cells
Western blotting confirmed expression of hVMAT1 variants in COS1 cells
transfected with hVMAT1 gene variants (Fig. 3). As shown in Fig. 3, loading of only 2 µg
of total protein was sufficient to observe marked immunoreactiveVMAT1 protein bands at
63 and 29 Kd . There were no differences in electroporetic mobility of the proteins on
gels. The translated hVMAT1 protein sequence NP_003044.1 consists of 525 amino acids
and a molecular size of 56 Kd (calculated with the Science Gateway Protein Molecular
Weight Calculator at http://www.sciencegateway.org/tools/proteinmw.htp), but the major
imunoreactive hVMAT1 proteins observed were 63 and 29 Kd. The 63 Kd size is
consistent with evidence for phosphorylation and glycosylation of VMATs (7). The 29 Kd
protein is hypothesized to be a truncated form lacking transport activity, as vesicular
transporters usually have 12 membrane-spanning domains that yield molecular weights
greater than 50 Kd (6).

Time-course of Serotonin Uptake by hVMAT1 Variants
The time course of radiolabeled serotonin uptake by protein extracts from cells
transfected with hVMAT1-a (Thr4 Ser98 Ile136) or hVMAT-98Thr (Thr4 Thr98 Ile136)
or hVMAT-1 4Pro (Pro4 Ser98 Ile136) increased steadily and was approximately linear
15

over at least 5 min (Fig. 4). Serotonin uptake by protein from wild type cells did not
increase over time. There were no statistical differences in the uptake of serotonin by
hVMAT1a and hVMAT-98Thr over 15 minutes, but the time course of radiolabeled
serotonin uptake by hVMAT1- 4Pro differed significantly from both hVMAT1-a and
hVMAT-98Thr. A quantitative comparison of serotonin uptake measured at 5 min is
shown in Fig. 5.

Inhibition of hVMAT1 Variants by Reserpine
The first studies of response to inhibitors were performed with the VMAT
inhibitor reserpine, and these studies were used to establish methodology for subsequent
assays. Preliminary inhibition curves were performed with extracts from 7 transfections
of each of two variants. These data (not shown) identified occasional spurious results
demonstrating the necessity for additional repetition to verify the reproducibility of results.
Fig. 6 illustrates average inhibition curves for effects of reserpine on radiolabeled
serotonin uptake by the variant protein cell extracts. The average IC50 (Table 3) of
reserpine inhibition was significantly greater for the hVMAT with a 4Pro/Ser98 (Pro4
Ser98 Ile136) than for the 4Thr/98Thr (Thr4 Thr98 Ile136) (P < 0.05). Reserpine
inhibition of hVMAT1-a (Thr4 Ser98 Ile136) and hVMAT-98Thr (Thr4 Thr98 136 Ile)
did not differ significantly.
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Inhibition of Serotonin Uptake by hVMAT1 Variants by Dopamine
Dopamine inhibition of serotonin uptake by protein extracts from cells transfected
with expression vectors carrying the three different haplotypes (Fig. 7 and Table 3) did not
differ significantly.

Saturation Kinetics of Serotonin Uptake by Human VMAT1 Variants
Saturation studies were performed at 1.5 min in an attempt to achieve initial
velocity of transport. As shown in Fig. 8 and Table 4, the transport Vmax of the hVMAT1a (Thr4 Ser98 Ile136) and hVMAT-98Thr (Thr4 Thr98 Ile136) variants was greater than
that of hVMAT-4Pro (Thr4 Ser98 Ile136). Although the transport Km of the 4Pro/Ser98
variant protein was slightly lower than that of the other variants, the difference was not
significant (Table 4). In time course studies performed with 20 nM radiolabeled serotonin
the variants hVMAT-1a (Thr4 Ser98 Ile136) and hVMAT-98Thr (Thr4 Thr98 Ile136) did
not differ significantly, and with saturating concentrations of radiolabelled serotonin, the
transport Vmax of these variants also did not differ significantly (Fig. 8 and Table 4).
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Discussion
This study provides new information on the functional and biochemical effects of
single nucleotide polymorphisms in the human VMAT1 gene that have been linked to
psychiatric disorders. This information is anticipated to provide clues to mechanisms that
account for linkage of these SNPs to schizophrenia and other psychiatric disorders.
Genetic linkage studies performed by several laboratories suggest that the proline at
position 4 is associated with increased susceptibility to schizophrenia in Han Chinese and
western European populations (2;3;14). The results of the present study indicate that the
hVMAT-1 4Pro/98Ser haplotype is associated with a decrease in transport activity
compared with other haplotypes in this study (Fig. 4 and 5), This finding is consistent with
evidence that reduced storage of monoamines in the brain and adrenal medulla and
potential disruption of regulatory mechanisms of adrenal-hypothalamic-pituitary
interactions will increase susceptibility to mood and behavioral disorders and potential
changes in cognitive functions (15). The transport Km of this haplotype was slightly but
not significantly lower than that of the other variants. It appears unlikely, therefore, that a
higher affinity for substrate could compensate for the reduced maximal function of the
4Pro variant. Furthermore, there were no detectable differences among the variants in
response to dopamine inhibition of serotonin uptake.
There were no significant differences in transport function between the 4Thr/98Thr
and 4Thr/98Ser haplotypes. Although the SNP coding for either a threonine 98 or a serine
18

98 has been linked to schizophrenia in both Chinese and Japanese populations (3;20), it is
a different allele in each population that is more frequent in schizophrenic patients. This
raises the possibility that other factors in combination with a specific 98 amino acid may
increase susceptibility to schizophrenia. The more prominent effect on transport of the
SNP coding for a 4 proline may be because of its location in the cytoplasmic N-terminus.
Additionally, there is evidence for phosphorylation for VMATs (7), and whereas both
threonine and serine can be phosphorylated, proline is not a substrate for phosphorylation.
It is clear that changes in VMAT1 in brain could alter storage of monoamine
neurotransmitters, but an additional hypothesis linking changes in VMAT1 to mood and
behavioral changes is based on the function of VMAT1 in storing epinephrine in vesicles
in the adrenal medulla. These vesicles are primed at the plasma membranes to be
exocytosed when triggered. VMAT-1 is the major vesicular monoamine transporter that
functions in adrenal medullary storage and regulated release of catecholamines,
particularly epinephrine, in rodents as well as humans (7). Decreased function of VMAT-1
in the adrenal medulla will reduce storage and release of adrenal catecholamines, which
may produce a deficiency of the rapid mechanism responsible for alleviating hypoglycemia
during fasting or stress (4). Assuming that the 4Pro haplotype would cause less
epinephrine to be stored and released, less epinephrine will be available to stimulate
mechanisms that alleviate hypoglycemia. Persistent hypoglycemia during epinephrine
deficiency will stimulate increased release of corticotropin-releasing hormone (CRH),
adrenocorticotropic hormone (ACTH) and corticosteroids, and glucagon. Increased
19

production of CRH and continuing elevation of plasma corticosteroids increase
susceptibility to depression and anxiety (15) and alter cognitive neural pathways in the
hippocampus and striatum (15;21)
In summary, this study suggests that a proline at position 4 in hVMAT1 causes a
modest reduction in VMAT1 transport function and alters its response to the inhibitor
reserpine. In contrast, the exchange of a threonine for a serine at position 98 in the protein
appears to have little effect on transporter function. Additional study is needed to clarify
the functional consequences of the Thr136Ile polymorphism in hVMAT1 and
combinations of amino acid changes at the 4, 98, and 136 positions.

20

Results Figures
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Figure 3. Immunoreactive human VMAT-1 assayed by western blotting. Beta actin
loading controls are shown below each lane. Total protein (2 µg per lane) was separated by
SDS-PAGE on 10 % gels. Lane 1= COS1 cells+hVMAT1a (4Thr/98Ser/136Ile); 2 =
COS1+hVMAT1 (4Thr/98Thr/136Ile); 3 = COS1+hVMAT1 (4Pro/98Ser/136Ile); 4 =
COS WT cells. The arrow indicates a 63 kD protein hypothesized to be the major active
hVMAT1 protein.
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Figure 4. Time course of serotonin uptake by human VMAT1 variants. Uptake of
radiolabeled serotonin ([3H] 5HT) by protein extracts from wild type (WT) COS1 cells
or cells transfected with expression vectors carrying human VMAT1 with
polymorphisms coding for a threonine or serine at amino acid 98 and threonine or
proline at amino acid 4. The data represent the mean ± S.E. of 3 transfections for each
variant. Uptake of each variant was significantly greater than that of WT cells at each
time point. Uptake by hVMAT1 with a 4Pro was significantly less than that of the
hVMAT1a98Ser and hVMAT98Thr by two-way ANOVA and Newman Keuls’ posthoc test (* P < 0.01).
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Figure 5. Quantitative comparison of serotonin uptake at 5 minutes by human
VMAT1 variants. Comparison of radiolabeled serotonin ([3H] 5HT) by protein extracts
from wild type (WT) COS1 cells and cells transfected with expression vectors carrying
human VMAT1 with polymorphisms coding for a threonine or serine at amino acid 98 and
a threonine or proline at amino acid 4. Each bar represents the mean ± S.E. of 9-12
replicates from 3-7 transfections for each variant measured at 5 min incubation. All are
significantly different from wild type by one-way ANOVA and Newman Keuls’ post-hoc
test. * P < 0.01 compared to 4 PRO/98SER.
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Figure 6. Reserpine inhibition of serotonin uptake by human VMAT1 variants.
Protein extracts from cells transfected with expression vectors carrying human VMAT1
DNA coding for the different haplotypes were incubated for 5 minutes with vehicle or 5-6
concentrations of reserpine and tritium labeled serotonin. Each curve represents the
average of 3-5 curves run on 3-5 transfections of each variant with wild type values
subtracted. The average IC50 (Table 3) of reserpine inhibition was significantly greater for
the hVMAT1 with a 4Pro/Ser98 (Pro4 Ser98 Ile136) than for the 4Thr/98Thr (Thr4 Thr98
Ile136) based on 95% confidence limits of the best fit non-linear regressions.
.
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Figure 7. Dopamine inhibition of serotonin uptake by human VMAT1 variants.
Protein extracts from cells transfected with expression vectors carrying human VMAT1
DNA coding for the different haplotypes were incubated for 5 minutes with vehicle or 5-6
concentrations of dopamine and tritium labeled serotonin. Wild type values were
subtracted from each point. The average IC50 (Table 3) of dopamine inhibition of serotonin
uptake did not differ significantly among the three protein variants.
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Figure 8. Saturation kinetics of serotonin uptake by human VMAT1 variants. Curves
illustrate uptake of 1.0:1.2 radiolabeled:unlabeled serotonin over 1.5 min by protein
extracts from COS1 cells transfected with expression vectors carrying human VMAT1
with polymorphisms coding for a threonine or serine at amino acid 98 and threonine or
proline at amino acid 4. Each data point represents the mean ± S.E. of 3-5 replicates from
3 transfections per variant with wild type values subtracted. Transport Km and Vmax
values are in Table 4.
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Table 3. Inhibition of Human VMAT1 Variant Uptake of Serotonin
hVMAT1
Haplotype
4Thr/98Ser/
4Thr/98Thr
4Pro/98Ser

Reserpine IC50
(nM)
Mean ± S.E
169 ± 29
116 ± 31
271 ± 34*

Dopamine IC50
(µM)
Mean ± S.E.
0.92 ± 0.22
1.07 ± 0.21
0.70 ± 0.15

*P ≤ 0.05 compared to the IC50 of the 4Thr/98Thr haplotype based on 95% confidence
limits of the best fit non-linear regression.
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Table 4. Saturation Kinetics of Serotonin Transport
by Human VMAT1 Variants

*

hVMAT1
Haplotype

Km
µM
Mean ± S.E

4Thr/98Ser/
4Thr/98Thr
4Pro/98Ser

1.76 ± 0.48
1.68 ± 0.48
0.57 ± 0.22

Vmax
nmol/1.5 min(mg protein-1)
Mean ± S.E
31.53 ± 3.09
38.00 ± 3.53
19.17 ± 2.13*

P ≤0.05 compared to 4 Thr/98Ser and 4Thr98Thr based on 95% confidence limits of the
best fit non-linear regression.
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